Valuation: Ipsen S.A.

Market Cap 11.89B 13.31B 11.09B 10.07B 18.97B 1,287B 19.12B 133B 52.07B 655B 49.95B 48.87B 2,104B P/E 2026 *
12.1x
P/E 2027 * 12.2x
Enterprise Value 10.56B 11.82B 9.85B 8.95B 16.86B 1,144B 16.98B 118B 46.26B 582B 44.38B 43.42B 1,870B EV / Sales 2026 *
2.3x
EV / Sales 2027 * 2.04x
Free-Float
40.65%
Yield 2026 *
1.06%
Yield 2027 * 1.06%
1 day+0.49%
1 week-1.67%
Current month-1.53%
1 month-13.93%
3 months-16.57%
6 months-13.72%
Current year+18.21%
1 week 138.8
Extreme 138.8
142.8
1 month 138.8
Extreme 138.8
160.2
Current year 116.4
Extreme 116.4
173.1
1 year 113.2
Extreme 113.2
173.1
3 years 88.3
Extreme 88.3
173.1
5 years 77.62
Extreme 77.62
173.1
10 years 66.65
Extreme 66.65
173.1
Manager TitleAgeSince
Chief Executive Officer 59 2020-06-30
Chief Executive Officer 57 2019-12-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 2005-08-29
Chairman 68 2010-11-21
Director/Board Member 69 2012-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%-1.67% - - 13.31B
+2.70%+2.73%+40.91%+110.31% 1,060B
+1.44%-2.38%+36.83%+63.95% 623B
+1.75%+3.73%+16.55%+83.05% 480B
+0.60%-1.73%+62.98%+37.46% 352B
-1.85%+1.46%+21.56%+41.16% 345B
-1.43%+0.41%+11.31%+34.51% 274B
-1.12%-1.78%-5.62%+11.11% 249B
+2.60%-2.00%+39.77%+54.44% 223B
+1.82%-1.48%+25.75%+96.48% 182B
Average -0.20%-0.48%+27.78%+59.16% 420.89B
Weighted average by Cap. -0.30%+0.04%+31.44%+70.19%

Financials

2026 *2027 *
Net sales 4.59B 5.13B 4.28B 3.89B 7.32B 496B 7.37B 51.41B 20.09B 252B 19.27B 18.85B 812B 4.69B 5.25B 4.38B 3.98B 7.49B 508B 7.54B 52.6B 20.55B 258B 19.71B 19.29B 830B
Net income 1.02B 1.14B 951M 863M 1.63B 110B 1.64B 11.42B 4.46B 56.1B 4.28B 4.19B 180B 1.01B 1.13B 945M 859M 1.62B 110B 1.63B 11.36B 4.44B 55.8B 4.26B 4.17B 179B
Net Debt -1.33B -1.48B -1.24B -1.12B -2.12B -144B -2.13B -14.87B -5.81B -73.03B -5.57B -5.45B -235B -2.3B -2.58B -2.15B -1.95B -3.67B -249B -3.7B -25.81B -10.09B -127B -9.67B -9.47B -408B
Projected Income Statement - Annual - Ipsen S.A.
Logo Ipsen S.A.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change
26-10-05 €141.50 +0.50%
26-10-07 €144.30 +1.98%
26-10-06 €141.50 +0.50%
26-10-05 €140.80 +0.36%
26-10-02 €140.30 -1.06%
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Ipsen S.A.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
145.00EUR
Average target price
165.07EUR
Spread / Average Target
+13.84%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen S.A.